Diagnosis and management of neurofibromatosis type 1

Current Neurology and Neuroscience Reports

Volumn 1, Issue 2, 2001, Pages 162-167

  Korf, Bruce R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Learning Disability; Malignant Peripheral Nerve Sheath Tumor; Neurofibroma; Neurofibromatosis; Plexiform Neurofibroma

Indexed keywords

GUANOSINE TRIPHOSPHATE; NEUROFIBROMIN; RAS PROTEIN;

ANIMAL; BRAIN TUMOR; CAFE AU LAIT SPOT; CELL TRANSFORMATION; CHEMISTRY; DOMINANT GENE; FEMALE; GENETICS; GLIOMA; HUMAN; HYPERTENSION; LEARNING DISORDER; LEUKEMIA; MALE; METABOLISM; MOUSE; MOUSE MUTANT; NEUROFIBROMA; NEUROFIBROMATOSIS; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW; RHABDOMYOSARCOMA; SCOLIOSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; BRAIN NEOPLASMS; CAFE-AU-LAIT SPOTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, DOMINANT; GENES, NEUROFIBROMATOSIS 1; GLIOMA; GUANOSINE TRIPHOSPHATE; HUMANS; HYPERTENSION; LEARNING DISORDERS; LEUKEMIA; MALE; MICE; MICE, KNOCKOUT; NEUROFIBROMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTEIN STRUCTURE, TERTIARY; RAS PROTEINS; RHABDOMYOSARCOMA; SCOLIOSIS;

EID: 0035296612     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-001-0012-z     Document Type: Article

References (53)

1. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999, 89:1–6. DOI: 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8
2. Stumpf DA, Alksne JF, Annegers JF, et al.: Neurofibromataosis. Arch Neurol 1988, 45:575–578.
3. Gutmann DH, Aylsworth A, Carey JC, et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51–57. DOI: 10.1001/jama.278.1.51
4. DeBella K, Szudek J, Friedman JM: Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000, 105:608–614. DOI: 10.1542/peds.105.3.608
5. DeBella K, Poskitt K, Szudek J, Friedman JM: Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000, 54:1646–1651.
6. Ablon J: Parents’ responses to their child’s diagnosis of neurofibromatosis 1. Am J Med Genet 2000, 93:136–142. DOI: 10.1002/1096-8628(20000717)93:2<136::AID-AJMG11>3.0.CO;2-L
7. Messiaen LM, Callens T, Mortier G, et al.: Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000, 15:541–555. This paper demonstrates that use of a multistep process can result in a high rate of detection of NF1 gene mutations. Although the process is laborious, it offers an approach that may result in a diagnostic test for neurofibromatosis type 1. DOI: 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N
8. Fahsold R, Hoffmeyer S, Mischung C, et al.: Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet 2000, 66:790–818. This is the largest set of NF1 mutations reported to date. The clustering of missense mutations between exons 11–17 suggests the occurrence of a functional domain other than the GAP-related domain. DOI: 10.1086/302809
9. Lopez CC, Brems H, Lazaro C, et al.: Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Hum Mutat 1999, 14:387–393. DOI: 10.1002/(SICI)1098-1004(199912)14:6<520::AID-HUMU11>3.0.CO;2-K
10. Jenne DE, Tinschert S, Stegmann E, et al.: A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions. Genomics 2000, 66:93–97. DOI: 10.1006/geno.2000.6179
11. Correa CL, Brems H, Lazaro C, et al.: Unequal meiotic crossover: a frequent cause of NF1 microdeletions. Am J Hum Genet 2000, 66:1969–1974. This paper provides a likely explanation for the etiology of large NF1 deletions by unequal crossing over between two repeated sequences. DOI: 10.1086/302920
12. Riva P, Corrado L, Natacci F, et al.: NF1 microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet 2000, 66:100–109. DOI: 10.1086/302709
13. Dorschner MO, Sybert VP, Weaver M, et al.: NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 2000, 9:35–46. DOI: 10.1093/hmg/9.1.35
14. Tinschert S, Naumann I, Stegmann E, et al.: Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000, 8:455–459. DOI: 10.1038/sj.ejhg.5200493
15. McGaughran JM, Harris DI, Donnai D, et al.: A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999, 36:197–203.
16. Thakkar SD, Feigen U, Mautner VF: Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety. Neuroradiology 1999, 41:625–629. DOI: 10.1007/s002340050814
17. Chung CJ, Armfield KB, Mukherji SK, et al.: Cervical neurofibromas in children with NF-1. Pediatr Radiol 1999, 29:353–356. DOI: 10.1007/s002470050605
18. Creange A, Zeller J, Rostaing-Rigattieri S, et al.: Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999, 122(Pt 3):473–481. DOI: 10.1093/brain/122.3.473
19. DiMario FJ Jr, Langshur S: Headaches in patients with neurofibromatosis-1. J Child Neurol 2000, 15:235–238.
20. Ramanathan RC, Thomas JM: Malignant peripheral nerve sheath tumours associated with von Recklinghausen’s neurofibromatosis. Eur J Surg Oncol 1999, 25:190–193. DOI: 10.1053/ejso.1998.0625
21. Ferner RE, Lucas JD, O’Doherty MJ, et al.: Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000, 68:353–357. If confirmed, this could result in a method of distinguishing benign from malignant peripheral nerve sheath tumors. DOI: 10.1136/jnnp.68.3.353
22. Listernick R, Charrow J, Tomita T, Goldman S: Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1. J Neurooncol 1999, 45:185–190. DOI: 10.1023/A:1006338322266
23. Zudek J, Birch P, Friedman JM: Growth charts for young children with neurofibromatosis 1 (NF1) [letter]. Am J Med Genet 2000, 92:224–228. DOI: 10.1002/(SICI)1096-8628(20000529)92:3<224::AID-AJMG12>3.0.CO;2-J
24. Clementi M, Milani S, Mammi I, et al.: Neurofibromatosis type 1 growth charts. Am J Med Genet 1999, 87:317–323. DOI: 10.1002/(SICI)1096-8628(19991203)87:4<317::AID-AJMG7>3.0.CO;2-X
25. Carmi D, Shohat M, Metzker A, Dickerman Z: Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999, 103:1257–1262. DOI: 10.1542/peds.103.6.1257
26. Durrani AA, Crawford AH, Chouhdry SN, et al.: Modulation of spinal deformities in patients with neurofibromatosis type 1. Spine 2000, 25:69–75. DOI: 10.1097/00007632-200001010-00013
27. Ippolito E, Corsi A, Grill F, et al.: Pathology of bone lesions associated with congenital pseudarthrosis of the leg. J Pediatr Orthop 2000, 9:3–10.
28. Stevenson DA, Birch PH, Friedman JM, et al.: Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999, 84:413–419. DOI: 10.1002/(SICI)1096-8628(19990611)84:5<413::AID-AJMG5>3.0.CO;2-1
29. Heikkinen ES, Poyhonen MH, Kinnunen PK, Seppanen UI: Congenital pseudarthrosis of the tibia. Treatment and outcome at skeletal maturity in 10 children. Acta Orthop Scand 1999, 70:275–282. DOI: 10.3109/17453679908997807
30. Cutting LE, Koth CW, Denckla MB: How children with neurofibromatosis type 1 differ from “typical” learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000, 17:29–47. This is a thorough and careful study of the characteristics of learning disabilities in children with NF1. DOI: 10.1207/S15326942DN1701_02
31. Johnson NS, Saal HM, Lovell AM, Schorry EK: Social and emotional problems in children with neurofibromatosis type 1: evidence and proposed interventions. J Pediatr 1999, 134:767–772. DOI: 10.1016/S0022-3476(99)70296-9
32. Zoller ME, Rembeck B: A psychiatric 12-year follow-up of adult patients with neurofibromatosis type 1. J Psychiatr Res 1999, 33:63–68. DOI: 10.1016/S0022-3956(98)00052-1
33. Cutting LE, Koth CW, Burnette CP, et al.: Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1. J Child Neurol 2000, 15:157–160.
34. Moore BD III, Slopis JM, Jackson EF, et al.: Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000, 54:914–920.
35. Kayl AE, Moore BD III, Slopis JM, et al.: Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention-deficit hyperactivity disorder. J Child Neurol 2000, 15:90–96.
36. DiMario FJ Jr., Ramsby GR, Burleson JA: Brain morphometric analysis in neurofibromatosis 1 [comment]. Arch.Neurol 1999, 56:1343–1346. DOI: 10.1001/archneur.56.11.1343
37. Griffiths PD, Blaser S, Mukonoweshuro W, et al.: Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics 1999, 104:e49. DOI: 10.1542/peds.104.4.e49
38. Rasmussen SA, Overman J, Thomson SA, et al.: Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chrom Cancer 2000, 28:425–431. DOI: 10.1002/1098-2264(200008)28:4<425::AID-GCC8>3.0.CO;2-E
39. Eisenbarth I, Beyer K, Krone W, Assum G: Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet 2000, 66:393–401. DOI: 10.1086/302747
40. Kluwe L, Friedrich R, Mautner VF: Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chrom Cancer 1999, 24:283–285. This paper provides some of the first evidence that it is the Schwann cell that is the primary neoplastic cell in a neurofibroma. DOI: 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K
41. Rutkowski JL, Wu K, Gutmann DH, et al.: Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000, 9:1059–1066. This paper provides some of the first evidence that it is the Schwann cell that is the primary neoplastic cell in a neurofibroma. DOI: 10.1093/hmg/9.7.1059
42. Feldkamp MM, Angelov L, Guha A: Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999, 51:211–218. DOI: 10.1016/S0090-3019(97)00356-X
43. Cichowski K, Shih TS, Schmitt E, et al.: Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172–2176. This paper describes the mouse knockout models of NF1, which have provided major insights into the pathogenesis of the disorders. DOI: 10.1126/science.286.5447.2172
44. Vogel KS, Klesse LJ, Velasco-Miguel S, et al.: Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176–2179. This paper describes the mouse knockout models of NF1, which have provided major insights into the pathogenesis of the disorders. DOI: 10.1126/science.286.5447.2176
45. Atit RP, Crowe MJ, Greenhalgh DG, et al.: The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 1999, 112:835–842. This paper provides evidence for a heterozygous effect of NF1 mutation. DOI: 10.1046/j.1523-1747.1999.00609.x
46. Ingram DA, Yang FC, Travers JB, et al.: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000, 191:181–188. This paper provides evidence for a heterozygous effect of NF1 mutation. DOI: 10.1084/jem.191.1.181
47. Birnbaum RA, O’Marcaigh A, Wardak Z, et al.: Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 2000, 5:189–195. DOI: 10.1016/S1097-2765(00)80415-3
48. DeClue JE, Heffelfinger S, Benvenuto G, et al.: Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000, 105:1233–1241. DOI: 10.1172/JCI7610
49. Mashour GA, Wang HL, Cabal-Manzano R, et al.: Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol 1999, 113:398–402. DOI: 10.1046/j.1523-1747.1999.00699.x
50. Guo HF, Tong J, Hannan F, et al.: A neurofibromatosis-1-regulated pathway is required for learning in Drosophila [comment]. Nature 2000, 403:895–898. DOI: 10.1038/35002593
51. Mahgoub N, Taylor BR, Gratiot M, et al.: In vitro and in vivo effects of a farnesyltransferase inhibitor on NF1-deficient hematopoietic cells. Blood 1999, 94:2469–2476.
52. Adjei AA, Erlichman C, Davis JN, et al.: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000, 60:1871–1877.
53. Scharovsky OG, Rozados VR, Gervasoni SI, Matar P: Inhibition of ras oncogene: A novel approach to antineoplastic therapy. J Biomed Sci 2000, 7:292–298.